Molnupiravir

Factory Location: CHANGZOU

Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Asia,Middle East

Monthly Production Capacity: 1000KGS

Packaging Information: 25KGS

Delivery Lead Time: AT ONCE

Sample Provided: no

Payment Terms: L/C

Molnupiravir

2349386-89-4

Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells. A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine. Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021.